The Lundquist Institute for Biomedical Innovation at Harbor-UCLA (TLI) announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a new grant (P01AI186818) to Dr. Ashraf S. Ibrahim, PhD, a TLI Investigator, a Professor of Medicine at David Geffen School of Medicine at UCLA, and a leading authority on mucormycosis pathogenesis. The grant provides $2.2 million in first-year funding and $11,269,858 million in total projected support over the next five years to launch MUCOR-ADVANCE, an ambitious effort to revolutionize risk stratification, early diagnosis, and treatment of mucormycosis, one of the world’s most lethal fungal infections.

Van Andel Institute scientists have developed an improved technique to comprehensively profile DNA methylation in single cells, an advance that will help researchers better study the role of epigenetics in cancer and other diseases.